Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Breast Cancer”

402 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 402 results

Not applicableStudy completedNCT01686412
What this trial is testing

Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency

Who this might be right for
Hepatocellular CarcinomaBreast Cancer
Hospital Sirio-Libanes 60
Not applicableStudy completedNCT02608281
What this trial is testing

Evaluation of Diagnostic Accuracy of Contrast Enhanced Dual Energy Mammography Imaging in Comparison to CE-MRI

Who this might be right for
Breast Cancer Diagnosis
Siemens Healthcare QT 110
Not applicableActive Not RecruitingNCT04595435
What this trial is testing

IORT-Breast at Medical Center Navicent Health

Who this might be right for
Breast Cancer FemaleEarly-stage Breast Cancer
Wake Forest University Health Sciences 94
Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Large-scale testing (Phase 3)Not Yet RecruitingNCT06561607
What this trial is testing

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Not applicableLooking for participantsNCT05725265
What this trial is testing

LLLT for BCRL: a Randomized, Placebo-controlled Study

Who this might be right for
Breast Cancer Lymphedema
National Taiwan University Hospital 54
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Not applicableStudy completedNCT05796219
What this trial is testing

Automated Low Dose Risk Assessment Mammography (ALDRAM)

Who this might be right for
Breast Cancer
Manchester University NHS Foundation Trust 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)Looking for participantsNCT06298084
What this trial is testing

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Who this might be right for
Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast Carcinoma+1 more
Gustave Roussy, Cancer Campus, Grand Paris 152
Not applicableLooking for participantsNCT05831878
What this trial is testing

RC48-ADC in HER2-low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RenJi Hospital 36
Testing effectiveness (Phase 2)Looking for participantsNCT05911958
What this trial is testing

SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Who this might be right for
HER2 Low Breast Carcinoma
Henan Cancer Hospital 66
Not applicableStudy completedNCT02982564
What this trial is testing

Effect of Low vs Moderate-intensity Endurance Exercise on Physical Functioning Among Breast Cancer Survivors

Who this might be right for
Breast Neoplasms
University of Puerto Rico 142
Not applicableStudy completedNCT00583726
What this trial is testing

The Women's Healthy Lifestyle Study

Who this might be right for
Breast Cancer
University of Michigan 40
Testing effectiveness (Phase 2)Ended earlyNCT01067989
What this trial is testing

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Who this might be right for
ChemotherapyBreast Cancer, Metastatic
HaEmek Medical Center, Israel 22
Not applicableStudy completedNCT00897793
What this trial is testing

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Who this might be right for
Breast CancerColorectal CancerHead and Neck Cancer+2 more
Vanderbilt-Ingram Cancer Center 25
Testing effectiveness (Phase 2)Study completedNCT02806544
What this trial is testing

Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country

Who this might be right for
Breast CancerBreast Neoplasms
Vanderbilt University 35
Not applicableLooking for participantsNCT06877416
What this trial is testing

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Who this might be right for
Antibody-drug ConjugatesHER2-low Breast CancerBreast Neoplasms
Sun Yat-sen University 700
Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Load More Results